Disclosure Of Cash Flow Statement [Text Block]

ABIONYX Pharma - Filing #2810725

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Disclosure of cash flow statement [text block]
XXX.
Description of accounting policy for determining components of cash and cash equivalents [text block]
Cash and cash equivalents if different from statement of financial position [abstract]
Cash and cash equivalents
4 104 EUR
4 046 EUR
Cash and cash equivalents if different from statement of financial position
4 102 EUR
4 044 EUR
7 772 EUR
Income taxes paid (refund) [abstract]
Income taxes paid (refund), classified as operating activities
0 EUR
0 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.